This message was sent to ##Email##
Penn’s Dr. David Fajgenbaum will share his riveting personal medical story that has led him to develop a groundbreaking research method (“flipping it on its head”) for disease prevention and treatment.
December 20, 2016, Annapolis, MD – Named by Forbes magazine as one of the top 30 young scientists changing the world, Dr. David Fajgenbaum, MD, MBA, MSc, FCPP, who is revolutionizing the way medical research is conducted, will deliver the Keynote Address at the National Federation of Advanced Information Service’s (NFAIS™) 59th Annual Conference, February 26-28, 2017 at Alexandria, VA’s Hilton Old Town.
Abstract and Informative Case Report submission is open to physician-scientists, research scientists, clinicians and medical education professionals. This meeting multi-disciplinary, abstract submission is highly recommended for young investigators, fellows, junior scientists and trainees, who would benefit from close interaction with senior colleagues regarding their work. You may submit as many abstracts as you like; however only one abstract will be considered for an award.
Deadline: January 8, 2017 at 11:59PM CST
Extended Deadline: 11:59 PM EST on Sunday, January 8, 2017
The Eastern Regional Meeting provides an ideal venue to present your medical research and network with fellow clinical investigators and senior AFMR members. Submitted abstracts may be considered for
Hot topics for the 2017 Breakfast Workshop: Emerging Infections, Infectious Diseases and Auto-Immune Diseases. The Eastern Section Council encourages you to submit your symposium!
Registration Now Open!
Shared decision-making following disclosure of coronary heart disease genetic risk: results from a randomized clinical trial
Hayan Jouni, Raad A Haddad, Tariq S Marroush, Sherry-Ann Brown, Teresa M Kruisselbrink, Erin E Austin, Khader Shameer, Emma M Behnken, Rajeev Chaudhry, Victor M Montori, Iftikhar J Kullo
Journal of Investigative Medicine Dec 2016, jim-2016-000318; DOI: 10.1136/jim-2016-000318
Characterization of PABPN1 expansion mutations in a large cohort of Mexican patients with oculopharyngeal muscular dystrophy (OPMD)
Marisa Cruz-Aguilar, Caroline Guerrero-de Ferran, Jose Luis Tovilla-Canales, Angel Nava-Castañeda, Juan C Zenteno
Journal of Investigative Medicine Dec 2016, jim-2016-000184; DOI: 10.1136/jim-2016-000184
Effect of preceding medications on resuscitation outcome of out-of-hospital cardiac arrest
Shih-Wen Hung, Chien-Ming Chu, Chih-Feng Su, Li-Ming Tseng, Tzong-Luen Wang
Journal of Investigative Medicine Dec 2016, jim-2016-000264; DOI: 10.1136/jim-2016-000264
COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages
Iryna Voloshyna, Lora J Kasselman, Steven E Carsons, Michael J Littlefield, Irving H Gomolin, Joshua De Leon, Allison B Reiss
Journal of Investigative Medicine Dec 2016, jim-2016-000259; DOI: 10.1136/jim-2016-000259
Management of alcohol misuse in patients with liver diseases
Jennifer L Peng, Milan Prakash Patel, Breann McGee, Tiebing Liang, Kristina Chandler, Sucharat Tayarachakul, Sean O'Connor, Suthat Liangpunsakul
Journal of Investigative Medicine Dec 2016, jim-2016-000254; DOI: 10.1136/jim-2016-000254
Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient
Role of a Novel NQO1*2 Polymorphism
Dagmar F. Hernandez-Suarez, Karla Claudio-Campos, Javier E. Mirabal-Arroyo, Bianca A. Torres-Hernández, Angel López-Candales, Kyle Melin, Jorge Duconge
Multifocal Gastric Ulcers Caused by Diffuse Large B Cell Lymphoma in a Patient With Significant Weight Loss
Mark A. Gromski, Jennifer L. Peng, Jiehao Zhou, Howard C. Masuoka, Attaya Suvannasankha, Suthat Liangpunsakul
Evolutionary History of Multiple Dural Fistula
Braulio Martinez-Burbano, Edgar Patricio Correa Diaz, Carolina Jácome Sánchez
Symptomatic Type IV Dual Left Anterior Descending Coronary Artery
Kyriacos Papadopoulos, Georgios M. Georgiou, Evagoras Nicolaides
Multiple Brain Abscesses in an Immunocompetent Patient With Factor V Leiden Mutation
Saeed Zubair Zafar, Najwa Pervin, Sukesh Manthri, Mukul Bhattarai
Combined Spinal-Epidural for Vaginal Delivery in a Parturient With Takayasu’s Arteritis
Sean Patrick Clifford, Paul Brian Mick, Brian Matthew Derhake
|Investigation of Methods to Reduce Mortality in Patients with Type II Myocardial Infarction (MI)
Our group investigates methods to reduce mortality in patients with Type II myocardial infarction (MI). Type II MI is said to occur when a patient has heart damage without obstruction of a coronary artery, and the signs and symptoms associated with an occluded coronary artery. Type II MI is commonly seen in critically ill patients and is due to a myocardial oxygen supply-demand mismatch, and when this occurs, mortality is increased two to four times that of patients who are equally ill but have no myocardial damage. There are no known treatments that reduce mortality in this high risk group.
Florence Rothenberg, MS, MD|
University of Cincinnati
Veterans Admin Medical Center
Because of the absence of studies designed to investigate treatments that will reduce mortality in this high risk group, we performed a large retrospective study of nearly 20,000 critically ill Veterans to identify if medications known to reduce mortality in Type I MI (typical obstruction of a coronary artery) are associated with reductions in mortality in critically ill patients with Type II MI. We found that beta-blockers, aspirin, and statins are all associated with reductions in mortality, but in a fashion that depends on the degree of heart damage and severity of illness. Those patients who were less ill or had lower levels of heart damage had lower rates of mortality if they were taking statins (but not aspirin or beta-blockers). In contrast, patients who were more ill or had a greater degree of heart damage were found to have lower mortality if they were taking aspirin or beta-blockers, but not statins.
Our group recently submitted a “Systematic Review of Beta-blocker, Aspirin, and Statin in Critically Ill Patients: Importance of Severity of Illness and Cardiac Troponin” to the Journal of Investigative Medicine. In this, we systematically reviewed the literature from the 1970’s to 2016 to identify studies that investigate mortality in critically ill patients who have been treated with either beta-blockers, aspirin, or statins. We found a similar relationship across the literature: statins appear to modify mortality in a less-ill population of patients who are critically ill, whereas beta-blockers and aspirin may impact those patients who are more severely ill. We also found significant literature that shows a direct relationship between the severity of illness and the degree of myocardial damage in this patient population. We believe this represents a significant body of literature to support prospective investigations of beta-blockers, aspirin, and statins, in the prevention of mortality in critically ill patients.
The AFMR has established a new webpage with the latest information on grants and funding opportunities. A number of resources have been added to assist with the grant writing process! Visit the Grants & Funding page for more information.
Registration and abstract submission are now open for Translational Science 2017! Join the brightest minds from across the spectrum of translational research April 19-21, 2017 in Washington DC.
Why Attend Translational Science 2017?
Submit Your Abstract by January 13
- EXPLORE the latest research, including sessions from today’s top minds in the field
- COLLABORATE with more than 900 scientific peers and leaders during unparalleled opportunities to create new connections
- EDUCATE yourself on key issues presented by plenary speakers
- INNOVATE your research by submitting a poster abstract, and gain visibility among peers and colleagues
Showcase your research and gain valuable exposure by submitting a poster abstract for Translational Science 2017! Don't miss out on the chance to share your work with peers and leaders and find new opportunities for collaboration.
Visit the Translational Science 2017 website to learn more, and to submit your abstract today. Don’t forget: you must be registered for Translational Science in order to have your abstract selected!
The AFMR’s mission is to develop and mentor tomorrow’s leaders in medical research. We invite our members and sister societies to share resources and opportunities for career growth, networking, grants and mentoring. We are reintroducing our Job Board and look forward to sharing your future opportunities!
The deadline to submit nominations is January 12, 2017. Visit the CR Forum website for more information.
- The Top Ten Clinical Research Achievement Awards honor outstanding accomplishments and major advances resulting from the nation's investment in research to benefit the health and welfare of its citizens.
- This prestigious national competition recognizes up to 10 winning research studies performed at U.S. institutions (see eligibility requirements).
- Eligible studies must have been published in a peer-reviewed journal during calendar year 2016.
- One study will be chosen to receive the Herb Pardes Clinical Research Excellence Award, which includes a cash prize of $5,000.
- Two studies will be chosen to receive the Distinguished Clinical Research Achievement Award, which includes a cash prize of $3,500 each.
- All winning studies will be featured at the Translational Science 2017 (April 19-20) as specially-recognized posters and in session presentations.
- All winning studies and their chosen representatives will be recognized at the Clinical Research Forum's Awards Dinner in Washington, D.C.
- All winning studies and their chosen representatives will be featured in a Top Ten video, released to the press and posted on CR Forum social media.
- All chosen representatives of winning studies will receive a travel stipend and hotel accommodations to attend the Awards Dinner and Translational Science 2017.
In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage. NF1 affects 1 in 3,000 people. The study results appeared Dec. 29, 2016, in the New England Journal of Medicine.
In October, the National Institutes of Health (NIH) sought input regarding the inclusion of preprints and other interim research products, such as protocols and large datasets, in grant applications and reports as a way to enhance the rigor and impact of research funded by the agency. Following extensive consultation with its member societies, FASEB submitted comments that highlighted five key concerns regarding the inclusion of these materials in NIH grant applications and reports:
Find out more on the FASEB website.
- The lack of a clear definition of “preprint” and a method for distinguishing work that has undergone some form of peer review
- The risk of an increased workload and burden for study section reviewers
- Negative effects on rigor and reproducibility of research in the absence of peer review
- Challenges of balancing application criteria to ensure sound science while supporting early career investigators
- The need to provide stakeholders with ample time to accommodate potential changes in application policies.
The National Institutes of Health Common Fund announced today the first awards for the Molecular Transducers of Physical Activity in Humans Program, which will allow researchers to develop a comprehensive map of the molecular changes that occur in response to physical activity. Nineteen grants will support researchers across the country to collect samples from people of different races, ethnic groups, sex, ages, and fitness levels. The samples will be analyzed to uncover how physical activity changes the chemical molecules within our bodies, which could lead to people engaging in more targeted and optimized types of activity
The leadership of the AFMR encourages you to submit your abstracts and attend our 2017 Regional Meetings for a great networking opportunity. We look forward to seeing you there!
Armand A. Krikorian, MD, FACE
Western Medical Research Conference (WMRC)
January 26-28, 2017 - Sunset Center | Carmel, CA
Review 2016 WRM published abstracts in the Journal of Investigative Medicine.
Discounted Pre-registration Deadline: January 13, 2017
Southern Regional Meeting (SRM)
February 11-13, 2017 - InterContinental Hotel | New Orleans, LA
Please note that the 2017 SRM will now be held February 11-13, 2017 (Saturday-Monday) instead of February 16-18. The SRM Program Planning Committee invites you to submit your abstract! Review the 2016 SRM published articles in the Journal of Investigative Medicine.
Discounted Pre-registration Deadline: February 9, 2017
Eastern Regional Meeting (ERM)
April 18, 2017 - Marriott Wardman Park | Washington, DC
Review 2016 ERM published abstracts in the Journal of Investigative Medicine. Registration now open!
Download Registration Form
Midwestern Regional Meeting (MWRM)
April 20-21, 2017 - The Mid-America Club | Chicago, IL
The MWRM Program Planning Committee invites you to submit your abstract! Review 2016 MWRM published abstracts in the Journal of Investigative Medicine.
MWRM Submission Deadline: Sunday, January 8, 2017
Discounted Pre-registration Deadline: April 13, 2017
For more information please visit the AFMR website.
AFMR will sponsor 2 symposia at next year’s Experimental Biology meeting, to be held on Saturday, April 23, 2017 in Chicago, IL.
New Insights into Insulin Resistance-Molecular Mechanisms and Therapeutic Implications
Chairs - Sharma Prabhakar(pictured left), MD, MBA, FACP, FASN, and Meredith Hawkins, MD, MS
Small GTPases: Basic Science to Translational Research
Chairs - Yutong Zhao(pictured right), MD, PhD and Anna Birukova, MD
We look forward to seeing you there!
Experimental Biology is the annual meeting of six societies comprised of more than 14,000 scientists and 50 guest societies.
Primary focus areas include anatomy, biochemistry and molecular biology, investigative pathology, nutrition, pharmacology, and physiology. EB 2017 is open to everyone with interest in the latest research impacting life sciences. Attendees represent scientists from academic institutions, government agencies, non-profit organizations and industry
Review 2016 published abstracts in the Journal of Investigative Medicine:
The Journal of Investigative Medicine (JIM) showcases the latest basic, clinical and translational research in a multidisciplinary forum. It is unique by publishing biomedical advances, as well as changes affecting the clinical research community, including abstracts from the AFMR’s 4 Regional Meetings. This is consistent with AFMR’s mission to develop and mentor tomorrow’s leaders in medical research. JIM was introduced in 1997 and is currently published by BMJ, offering 8 issues per year.
We invite you to submit a manuscript! There are no page charges for AFMR members whose manuscripts are published in JIM. Not a member? Join AFMR and enjoy the many benefits that membership provides!
To help further your research, you are invited to publish your case reports in the Journal of Investigative Medicine High Impact Case Reports, an Open Access journal from the AFMR, and published by SAGE. The AFMR is committed to enhancing the training and professional growth of its members, as well as to furthering its mission to facilitate the conduct of research to improve medical care. The publication of high quality case reports represents a critical element of investigative medical science and is an important avenue for career development. Should you choose to become an AFMR member, you would receive a 50% discount on the fee to publish your case report in the journal. You may access the online submission site to submit or to learn more about the publication and review the instructions for authors. The Journal of Investigative Medicine High Impact Case Reports is indexed on PubMed Central. If you have any questions about submitting, please email the National Office for assistance.
Michael McPhaul, MD
Do you know a current AFMR member who is active in the field and deserves to be recognized for their outstanding or groundbreaking work? Nominate your colleague to be featured in our Member Spotlight section of Insights! Submit their story to us at email@example.com for the opportunity to be in the spotlight and recognized worldwide!
FASEB represents more than 125,000 scientists and engineers through collaborative advocacy with constituent societies. Our top priority is urging Congress to provide sustainable and predictable federal funding for scientific research.
But it’s not enough for organizations like FASEB to advocate for science—policymakers want to hear from constituents, too. There are many ways to deliver messages, ranging from privately meeting your legislator to attending a campaign event or town-hall meeting. The key is to evaluate your goals, the specific context and messages, and weave them together into a winning mix.
Join our advocacy efforts to ensure the U.S. continues to be a hub for innovation and scientific discovery. The resources below provide a set of practical tools to communicate with elected officials and the public.
As you review your annual giving for the upcoming year, I would like to ask you to consider a gift to the American Federation for Medical Research. Your contribution will be used to support AFMR-sponsored activities and we need your support.
With your generous donation, we can continue to offer innovative programs to help our members advance their careers at government facilities; medical centers; universities and medical schools; research institutions; and private industry in all 50 states and throughout the world. The AFMR provides young and aspiring trainees with scholarships and travel grants to attend regional meetings offering them the opportunity to present their findings to their peers and receive the guidance of senior scientists. The AFMR also recognizes trainees with national awards, such as the Henry Christian awards, named after the founder of the organization, Dr. Henry Christian. The AFMR strives to foster the development of future generations of clinical scientists and investigators through its initiatives, while encouraging public, private, and governmental investment in the development of these individuals.
Contributions are tax-deductible. Whether you choose to contribute $50, $100, $250, or another amount, I urge you to participate. I also welcome your suggestions or ideas about other potential sponsors for our programs. Most importantly, we thank you if you made a donation in 2016.
Please click here if you would like to make an online donation in 2017.
Leticia M. Ryan, MD, MPH
|Jan. 26-28, 2017
||Western Medical Research Conference
|Feb. 11-13, 2017
||Southern Regional Meeting
||New Orleans, LA
|April 18, 2017
||Eastern Regional Meeting
|April 18-21, 2017
||Translational Science 2017
|April 20-21, 2017
||2017 Combined Annual Meeting of CSCTR & MWAFMR
|April 22-26, 2017
|| Experimental Biology 2017
| || |
Connect with AFMR
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Natalie Thomas, Assistant Executive Editor, 469-420-2635 | Contribute news
MingMing Ning, AFMR Chair, Publishing Committee, 978-927-8330 | www.afmr.org
Elissa Klein, AFMR Executive Director, 978-927-8330 | www.afmr.org
Nicole Pinkham, AFMR Administrator, 978-927-8330 | www.afmr.org
American Federation for Medical Research
500 Cummings Center, Suite 4550 | Beverly, MA 01915 | 978-927-8330 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063